NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
On November 13, 2026, NeOnc CEO Amir Heshmatpour purchased 30,000 shares at open market, bringing his 2026 total to 371,000 shares for >$1.5M in personal funds (no company issuance). Separately, updated Phase 2a interim results for NEO100 (intranasal perillyl alcohol, recurrent IDH1-mutant glioma, N=24) showed objective response rate improved to 12.5% (3 of 24 patients) from 8.3% (2 of 24) in August topline; median overall survival 26.1 months from recurrence vs ~6–9 month historical benchmark; 66.7% disease control. Primary endpoint (PFS-6 48.9% vs 20% protocol threshold, p=0.0047) already met in August. Single-arm, open-label study without concurrent control. FDA Type B meeting scheduled early January 2027 to discuss potential accelerated approval pathway for Phase 3.
Why this rating
Clinical data reinforces early-stage efficacy signal in unmet need (recurrent high-grade glioma). CEO's $1.5M open-market purchase signals confidence but is small relative to $67.9M market cap (~2.2%). Phase 3 pathway hinges on FDA acceptance of single-arm data for Accelerated Approval—regulatory risk remains material.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.